Over the past weeks I’ve been thinking about the PCOS/PMOS name change a lot.
I have PCOS - or PMOS, as it’s now officially called and my diagnosis years ago is what pulled me into the women’s health space in the first place. It’s the reason Femtech Insider exists.
Many of you have asked what I think about the change. And it’s taken me a few days to sort through it, because my honest answer is: It’s complicated. The new name is better. The process behind it was serious. And I’m still not sure it’s enough. So here’s where I’ve landed (for now…).
What Happened
On May 12, a global consensus study published in the Lancet formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). This wasn’t a quick decision. The debate started in 2015, when a group of experts meeting in Sicily agreed the name was bad but couldn’t agree on a replacement. Over the following decade, surveys gathered input from approximately 22,000 patients and clinicians across 6 continents, 56 academic, clinical, and patient organizations were involved, and the final vote was near-unanimous: 87 out of 90 panel members supported the new name. It has been described as the largest medical renaming effort ever undertaken.
The case for change was straightforward. “Polycystic ovary syndrome” implies the presence of ovarian cysts - but the “cysts” seen on ultrasound are actually arrested follicles, not pathological cysts. The name reduced a complex, multisystem condition to a single organ, leading clinicians and patients alike to think of it as primarily a gynecological problem. In reality, PCOS involves interacting disturbances in insulin signaling, androgen production, neuroendocrine pathways, and ovarian function - with impacts on weight, metabolic health, cardiovascular risk, mental health, skin, and fertility. The WHO estimates that 70% of people with PCOS are undiagnosed. The misleading name possibly played a role in that.
The new name now leads with what the condition actually is: Polyendocrine (multiple interacting hormonal disturbances), metabolic (insulin resistance, cardiometabolic risk), ovarian (recognizing but not overemphasizing the reproductive dimension.
The Criticism Is Worth Taking Seriously
Not everyone is on board though. And the concerns that have been raised deserve engagement, not dismissal.
PCOS Challenge, the largest U.S. patient advocacy organization for the condition, released a detailed and carefully worded response. Their position is more nuanced than a simple objection. They’re not saying the old name was fine. They’re saying: Documenting that the name caused harm and proving that renaming will fix it are different things. Diagnostic delays, underfunding, and fragmented care also reflect training gaps, referral patterns, reimbursement structures, and clinical jurisdiction. A new name can be adopted by classification systems and electronic health records - but that’s administrative uptake, not clinical reform.
They also raise a practical and from a communications standpoint very valid question that’s easy to overlook: Who pays? The organizations that have spent decades building advocacy infrastructure, patient education materials, clinical trial recruitment networks, and community support around the PCOS name now face real rebranding costs - new trademarks, new domains, reprinted materials, updated books and apps. That burden falls disproportionately on the community that’s been doing the work. For many in the PCOS community, as PCOS Challenge noted, this change is complicated.
There’s also a scientific critique worth noting. Keeping “ovarian” in the name excludes emerging research on a potential male expression of the condition.
A Name Is a Name
Something I’ve already noticed in patient support groups: People correcting others for saying “PCOS.” Insisting it’s PMOS now. Policing the language.
I understand the impulse - there’s a sense of progress, and people want to honor it. But in a way this misses the point. A woman searching for answers about her symptoms, her weight, her fertility, her mental health - she does not need to be told she’s using the wrong acronym. She needs better care. She needs a doctor who understands the metabolic dimensions of her condition, a referral pathway that doesn’t bounce her between specialists for years, and a healthcare system that takes her seriously regardless of what the acronym on her chart says.
The new name is better. It’s more scientifically accurate. But it’s still a syndrome label for what is actually a heterogeneous set of conditions. Different patients have different drivers - insulin resistance in some, androgen excess in others, neuroendocrine dysregulation in others still. PMOS groups them all under one umbrella, just as PCOS did. The real progress will come when we can define subtypes and phenotypes precisely enough to treat the underlying drivers in each patient individually. That’s what precision medicine promises. It’s what 170 million women deserve. And a name change, however well-intentioned, probably won’t get us there on its own.
What Actually Needs to Happen
The Lancet paper includes an 8-stage global implementation plan with a 3-year managed transition. Most of these stages are about dissemination - publishing, communications, resource development. But the stages that will determine whether this changes outcomes or just terminology are the structural ones: Embedding the new name into electronic health records and coding systems, so that clinicians actually see PMOS when they’re diagnosing and coding. Aligning research funding categories and classification systems with governments, regulators, and funding bodies, so that studies of the metabolic and cardiovascular dimensions of the condition aren’t siloed under gynecology. And formal engagement with the WHO and inclusion in the International Classification of Diseases.
The plan also includes embedding PMOS into the International 2028 guideline update, used across 195 countries. That will almost certainly happen - the guideline is developed by the same network that led the renaming effort. But adoption by the guideline’s own authors isn’t the same as adoption by the broader system. The real test is what happens beyond the consensus group: Whether EHR vendors update their systems, whether national health services adopt the terminology, whether medical schools teach it, whether insurers recognize PMOS codes for reimbursement, and whether research funders actually reclassify their categories. That’s the infrastructure that determines whether patients feel the difference.
What This Tells Us Beyond PMOS
There are lessons here that extend well beyond this one condition. How a condition is named and classified can influence how it’s perceived, which specialty claims it, and how easily it fits into existing funding and research categories. It’s one factor among many - naming alone doesn’t explain why women’s health conditions are underfunded, and changing a name alone won’t fix it. But framing does matter. Endometriosis is still primarily classified as a gynecological condition despite its systemic inflammatory dimensions. Menopause is categorized as a reproductive endpoint rather than a cardiometabolic risk transition. The PMOS renaming is an explicit attempt to shift that framing, and whether it succeeds or stalls will be worth watching for anyone working on advocacy in this space.
But the PCOS Challenge critique is worth internalizing across the industry too. The women’s health ecosystem has become good at awareness - naming conditions, destigmatizing them, building communities around them. That work is essential. But awareness on its own doesn’t become better care. If clinical education, referral pathways, and reimbursement structures don’t follow, patients don’t feel the difference. That’s a useful check for all of us.
The renaming is progress. It reflects what patients and clinicians have been saying for years. But it’s a starting point, not a destination. The name alone didn’t cause the decades of underfunding, dismissal, and fragmented care on its own - and changing it won’t fix those things on its own either.
What matters now is whether the implementation delivers, and whether the energy that went into renaming the condition translates into actually improving how it’s diagnosed, treated, and funded. That’s what I’ll be watching. And that’s what 170 million women are waiting for.
